Other News

Laplace Interventional Inc. Announces $7.9M Series A for its Transcatheter Tricuspid Valve Technology

The Series A was led by a major strategic investor along with a significant investment from ShangBay Capital as well as other investors. Laplace Interventional plans to use the funds raised from this round towards achieving its preclinical milestones. MINNEAPOLIS–(BUSINESS WIRE)–Minnesota based Laplace Interventional, a medical device company developing a […]

MedAlliance Announces First Patient Enrolled in the 3,300 Patient Landmark Sirolimus DEB vs DES Study

GENEVA, Sept. 1, 2021 /PRNewswire/ — MedAlliance is pleased to announce the enrollment of the first patient in the ground-breaking coronary randomized controlled study “SELUTION DeNovo”. This study utilizes SELUTION SLR™, a novel sirolimus drug-eluting balloon [DEB], versus a limus drug-eluting stent [DES]. This is the largest DEB study ever initiated, with […]

Cardax Refocuses on ZanthoSyn® Consumer Health Business

Company focusing on consumer revenue growth with reduced cost structure Pharmaceutical assets may be monetized through licensing or sale Other strategic alternatives under consideration Board of Directors restructured in connection with new strategy HONOLULU, Aug. 31, 2021 /PRNewswire/ — Cardax, Inc., announced today that it is refocusing its business strategy on its […]

KardiaMobile 6L is Superior to One Lead Personal Devices

MOUNTAIN VIEW, Calif., Sept. 1, 2021 /PRNewswire/ — AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced the KardiaMobile® 6L device was found to be superior to single lead devices according to results from the largest study to assess the reliability of the detection of atrial fibrillation (AF) through […]

Healogics® Raises Awareness of Peripheral Artery Disease (PAD) to Help Reduce Amputations

JACKSONVILLE, Fla., Sept. 1, 2021 /PRNewswire/ — Healogics, the nation’s leading provider of world-class wound care services, is raising awareness of Peripheral Artery Disease (PAD) throughout September. Through this campaign, Healogics is supporting the American Heart Association’s goal to reduce amputations by 20% by 2030 through increased PAD Awareness, diagnosis and treatment. […]

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)

Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a […]

Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company’s Chief Medical Officer (“CMO”). Dr. […]

First Patients in Canada Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

Introduction of Orbital Atherectomy in Canada Expands Treatment Options for Patients with Complex Coronary Artery Disease ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients […]

LifeTech Scientific Corporation Announces 2021 Interim Results

SHENZHEN, China, Aug. 30, 2021 /PRNewswire/ — LifeTech Scientific Corporation (LifeTech, 01302.HK), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced 2021 interim results. Compared with the first half of 2020, LifeTech achieved an outstanding performance. The revenue was approximately RMB461.1 million, increased by approximately 68.9%, the […]